Breaking
European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD
🇺🇸 FDA
News

The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities

This study analyzes the monoclonal antibody market, focusing on patent activity, pricing, and market concentration.

Dr. Yuki Tanaka Dr. Yuki Tanaka 10 min read Updated May 5, 2026
The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities


This research paper provides a comprehensive analysis of the monoclonal antibody (mAb) market, highlighting key trends and challenges.


About the Author

Dr. Yuki Tanaka
Dr. Yuki TanakaMD, PhD

APAC Regulatory Correspondent

Dr. Tanaka covers PMDA, NMPA, and TGA drug approval processes across the Asia-Pacific region.

PMDANMPAAsia-Pacific regulatory

Related Articles

Palvella Therapeutics Begins Phase 2 Trial of QTORIN Rapamycin for Rare Angiokeratomas
NewsMay 5, 2026

Palvella Therapeutics Begins Phase 2 Trial of QTORIN Rapamycin for Rare Angiokeratomas

Michael Rivera
Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment
NewsMay 5, 2026

Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment

Dr. Natalie Hughes
CAPLYTA (Lumateperone) Ranks Highest Among FDA-Approved Adjunctive Depression Treatments in Network Meta-Analysis
NewsMay 5, 2026

CAPLYTA (Lumateperone) Ranks Highest Among FDA-Approved Adjunctive Depression Treatments in Network Meta-Analysis

Dr. Sarah Mitchell
Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD
NewsMay 5, 2026

Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD

Dr. Priya Nandakumar